Explore India's potential in futuristic marine and space biotechnology to enhance biomanufacturing and strengthen its ...
The average one-year price target for MAIA Biotechnology (NYSEAM:MAIA) has been revised to $10.48 / share. This is a decrease ...
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation ...
Like other developing countries, Indonesia is facing a familiar dilemma: how to feed a growing population while protecting ...
24/7 Wall St. on MSN
Biotech Could Be One of 2026’s Biggest Winners, and This ETF Is Perfectly Positioned
Biotech investors spent years waiting for the sector to recover from its brutal 2021 peak. That patience is finally paying ...
A successful Phase 3 trial and a public offeringof stock boosted prospects for this company to receive approval for an ...
Sulfolobus islandicus, an archaeal model organism, offers unique advantages for metabolic engineering and synthetic biology ...
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter: Alumis: Top-line ...
Bucks County Congressman Brian Fitzpatrick arranged the tour to highlight biomedical innovation and public health leadership.
PARIS, France – December 18, 2025 – 10:05 pm CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback